ArticleInternational journal of laboratory hematology2026
Contribution of XN-10 Sysmex Parameters in the Cytological Monitoring of Acute Promyelocytic Leukemia.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe all-trans-retinoic acid (ATRA) treatment used in acute promyelocytic leukemia (APL) has the particularity of inducing differentiation of the leukemia cells. As a result, within the same smear, several stages of cellular differentiation of the granular lineage are present, which can make it difficult to distinguish elements when counting cells.
methodsThe aim of this study is to use the technical data from Sysmex haematology equipment in patients with APL to improve their cytological monitoring and harmonize blood count results from one operator to another. We collected 132 samples from patients with APL over a period of 45 days from the day of diagnosis and divided them into two groups: presence or absence of blast cells on the blood smear.
resultsSeven parameters of leukocyte subpopulations were selected for cytological monitoring. We developed a decision algorithm based on these, including decision thresholds for predicting the presence or absence of blasts. These data were verified on a validation cohort of 110 samples with APL, set up at a different site from the training cohort. The algorithm predicted the presence of blast cells in these samples with a sensitivity of 84.6% and a specificity of 86.7%.
conclusionIn the context of cytological monitoring of patients with APL, the study of technical data has not been developed yet, despite the fact that this is a difficult and sometimes nonhomogeneous task from one operator to another. The proposed algorithm could be a facilitating tool in cytology to harmonize practices both within and between sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.